BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Sep 1, 2017
Clinical News

FDA snubs Cardiome's Brinavess resubmission for AF

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess vernakalant (Kynapid, MK-6621) to treat atrial fibrillation (AF) would not be sufficient to support resubmission of an...
BC Extra | Aug 21, 2017
Company News

FDA snubs Brinavess resubmission for AF

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess vernakalant to treat atrial fibrillation would not be sufficient to support resubmission of an NDA. On Monday,...
BC Week In Review | Jan 26, 2015
Company News

Cardiome, Aspen deal

Cardiome granted Aspen exclusive rights to commercialize Cardiome’s IV Brinavess vernakalant in South Africa. The mixed ion channel antagonist is approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation...
BC Week In Review | Jan 5, 2015
Company News

Cardiome, Eddingpharm deal

Cardiome granted Eddingpharm rights to develop and commercialize atrial fibrillation drug IV Brinavess vernakalant in China, including Macau, and Taiwan. Eddingpharm also has rights to re-launch the mixed ion channel antagonist in Hong Kong. Cardiome...
BC Week In Review | Sep 22, 2014
Company News

Cardiome, Eurolab deal

Cardiome's Correvio International S.a.r.l. subsidiary granted Eurolab exclusive rights to commercialize IV Brinavess vernakalant in Argentina. The deal includes specific annual commercial goals but Cardiome said financial terms are not disclosed. The mixed ion channel...
BC Week In Review | Mar 31, 2014
Company News

Cardiome, Vianex S.A. sales and marketing update

Cardiome's Cardiome International A.G. subsidiary granted Vianex rights to commercialize IV Brinavess vernakalant in Greece. The renewable three-year deal includes specific annual commercial goals. Cardiome said financial terms are not disclosed, and the partners could...
BC Week In Review | Mar 24, 2014
Company News

Cardiome, Logista Pharma sales and marketing update

Cardiome granted Logista rights to commercialize IV Brinavess vernakalant in Spain. Cardiome said financial terms were not disclosed, and Logista could not be reached. The mixed ion channel antagonist is approved in the EU for...
BC Week In Review | Feb 24, 2014
Company News

AOP Orphan, Cardiome sales and marketing update

Cardiome said IV Brinavess vernakalant for atrial fibrillation (AF) is now available in Switzerland, the Czech Republic, Poland, Slovenia, Hungary, Latvia and Romania. Cardiome said Brinavess is already available in Austria. Last July, Cardiome granted...
BioCentury | Feb 24, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) rose $1.21 (24%) to $6.16 on Wednesday after FDA granted accelerated approval to Northera droxidopa to treat neurogenic orthostatic hypotension (NOH). The company plans to launch Northera next...
Items per page:
1 - 10 of 163